 |
|
|
| |
Initial Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450 When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary Results of Study M11-602 in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects
|
| |
| |
Reported by Jules Levin
61st Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting - October 29-November 2, 2010 - Boston, MA
Eric Lawitz1, Isabelle Gaultier2, Fred Poordad3, Daniel Cohen2, Rajeev Menon2, Lois M. Larsen2, Thomas Podsadecki2, Barry Bernstein2
1Alamo Medical Research, San Antonio, TX, United States; 2Global Pharmaceutical R & D, Abbott Laboratories, Abbott Park, IL, United States;
3Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, United States
|
| |
|
|
|
|
|
